M
MedgenLife Science
About Medgen

About Us

Medgen Life Science (迈捷生命科学) is a Shenzhen-based medical device company dedicated to developing and commercializing regenerative repair materials for orthopedic and dental applications.

Our Mission

Medgen Life Science was founded by a team with deep expertise in biomaterials science and medical device commercialization. We are committed to advancing the standard of care in bone regeneration through innovative, clinically validated products that address unmet needs in orthopedic and dental surgery.

The company was co-founded with support from the regenerative engineering institute of Professor Cato Laurencin, a distinguished scientist who holds the rare distinction of being elected to all three U.S. national academies — the National Academy of Medicine (NAM), the National Academy of Engineering (NAE), and the National Academy of Sciences (NAS). This academic collaboration provides Medgen with access to world-class research and a rigorous scientific foundation for product development.

Our product portfolio spans from injectable bone void fillers to xenograft materials, all developed using proprietary processing technologies that preserve the biological characteristics of natural bone tissue. With two NMPA Class III approvals achieved within months of each other, Medgen is establishing itself as a leader in China's regenerative repair materials market.

2
NMPA Class III Approvals
2016
Year Founded
2
Funding Rounds (2024-25)
3
Technology Platforms

Academic Foundation

Co-founded with the support of Prof. Cato Laurencin's regenerative engineering institute. Prof. Laurencin is the only living individual elected to all three U.S. national academies (NAM, NAE, NAS), providing Medgen with an unparalleled scientific pedigree in regenerative medicine.

Technology Platform

Our product development is built on three core technology platforms, each representing years of research and engineering optimization.

Natural-Derived Biomaterial Processing

Proprietary processing techniques that preserve the native collagen matrix and mineral composition of natural bone tissue, yielding materials with superior osteoconductive properties compared to synthetic alternatives.

Controlled Porosity Architecture

Precision-engineered pore structures that optimize cell infiltration, nutrient transport, and vascularization. Our materials feature interconnected macro- and micro-porosity tailored for specific clinical applications.

Pre-Filled Delivery Systems

Innovative ready-to-use delivery systems that eliminate intraoperative mixing, reduce procedure time, and ensure consistent material performance. BoneSwift™ is China’s first pre-filled injectable bone repair product.

Company Milestones

A timeline of key events in Medgen's journey from founding to dual NMPA approvals.

2016

Company founded in Shenzhen

Medgen Life Science established with a focus on regenerative repair materials for orthopedic and dental surgery.

2017

Began distribution of Accuro™ ultrasound device

Entered the medical device market with distribution of the Accuro™ spinal ultrasound navigation system, building clinical relationships and commercial infrastructure.

2022

Entered CHTF Innovation Competition

Showcased proprietary biomaterial technology at the China Hi-Tech Fair, gaining industry recognition for our regenerative engineering platform.

2023

Won “China Medical Device Innovation & Entrepreneurship” competition

Recognized at the national level for innovation in regenerative repair materials. Ranked in the national top 100 "Sci-Tech China" program for medical device startups.

2024 Nov

Completed Series A funding

Raised tens of millions of RMB in Series A financing to accelerate product development and regulatory submissions.

2025 Jan

Completed Series A+ funding

Closed a follow-on Series A+ round, strengthening the balance sheet ahead of dual product launches.

2025 Mar

BoneSwift™ NMPA approval — China’s first pre-filled injectable bone repair material

Received NMPA Class III medical device approval for BoneSwift™, a breakthrough pre-filled injectable bone repair material with no mixing required.

2025 Apr

PoroGraft® NMPA approval — China’s first porcine-derived oral bone graft

Received NMPA Class III approval for PoroGraft®, a natural-derived xenograft material with controlled porosity for guided bone regeneration in dental implant procedures.

Get in Touch

Interested in learning more about Medgen Life Science? We welcome inquiries from hospitals, distributors, research institutions, and potential partners.

Contact Us